Vistagen Therapeutics, Inc. (VTGN) Stock Price, Financials & Summary

Price chart

Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18

Key dataSep 18, 2026

Open$0.23

From 52W high−94.95%

Volume687297.00

Market cap$10.98M

P/E (TTM)—

P/S (TTM)4.4x

Div yield—

Key dataSep 18, 2026

Open

$0.23

From 52W high

−94.95%

Volume

687297.00

Market cap

$10.98M

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

0.3x

P/E (TTM)

—

RSI (14)

43.9

MomentumView details →

1D Return

+5.95%

YTD Return

−63.74%

SummaryUpdated Jun 1, 2026

VistaGen Therapeutics, Inc. (NASDAQ:VTGN) is a clinical-stage biopharmaceutical company founded in 1998 and headquartered in South San Francisco, California. The company specializes in developing novel treatments for central nervous system disorders, particularly anxiety and depression. VistaGen went public in 2011 and has built a pipeline of innovative nasal spray therapies that target brain neurocircuitry through a unique nose-to-brain delivery mechanism. The company is currently advancing multiple drug candidates through clinical trials, with its lead program for social anxiety disorder in Phase III development.

Ask drillr about Vistagen Therapeutics, Inc. →

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

0.3x

EV/Sales

−8.0x

P/S (TTM)

4.4x

P/B (TTM)

0.4x

ProfitabilityView details →

Gross Margin

84.57%

Net Margin

−2702.64%

EBITDA Margin

−2689.93%

ROE (TTM)

−276.21%

ROA (TTM)

−189.22%

Asset Turnover

0.06x

GrowthView details →

Revenue YoY

+287.31%

EPS YoY

+5.03%

FCF YoY

−24.13%

Revenue CAGR 3Y

+9.21%

EPS CAGR 3Y

−9.58%

EBITDA YoY

−17.20%

MomentumView details →

1D Return

+5.95%

YTD Return

−63.74%

1Y Return

−91.95%

RSI (14)

43.9

vs 50D SMA

−3.37%

vs 200D SMA

−66.17%

Capital & dividendView details →

Debt/Equity

0.03x

Current Ratio

3.07x

Quick Ratio

3.07x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

−$0.30

EPS Surprise

17.81%

Beats (12Q)

8/12

Next Q EPS Est

−$0.38

Avg Surprise (4Q)

8.90%

Rev Surprise

195.20%

Financials snapshotView financials →

Revenue (TTM)

2.50M

Net Income (TTM)

−67.62M

Op. CF (TTM)

−62.30M

Next earningsNov 12, 2026 →

Latest newsMore news →

Vistagen Therapeutics reported Q1 FY2027 revenue of $1.476 million, up 504.9% year-over-year, with a net loss of $13.03 million and diluted EPS of -$0.30.38d ago

Similar companies

Ainos, Inc.AIMD IN8bio, Inc.INAB MetaVia Inc.MTVA Lunai Bioworks Inc.LNAI KALA BIO, Inc.KALA CytoMed Therapeutics LimitedGDTC Find similar companies →

Latest newsMore news →

Vistagen announced it will present a poster at Psych Congress 2026 highlighting a positive efficacy signal for its fasedienol nasal spray in study participants with very severe social anxiety disorder.10d ago Vistagen Therapeutics reported Q1 FY2027 revenue of $1.476 million, up 504.9% year-over-year, with a net loss of $13.03 million and diluted EPS of -$0.30.38d ago Vistagen announced topline results from its exploratory Phase 2 repeat dose study of fasedienol nasal spray for social anxiety disorder, showing favorable safety and efficacy signals.45d ago